<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: We examined whether type of <z:mp ids='MP_0002055'>diabetes</z:mp> and/or insulin treatment can modulate the impact of sustained <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and glycaemic variability as activators of <z:mp ids='MP_0003674'>oxidative stress</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This was an observational study in 139 patients with <z:mp ids='MP_0002055'>diabetes</z:mp>, 48 with type 1, 60 with type 2 treated by oral hypoglycaemic agents (OHAs) alone and 31 with type 2 treated with insulin plus OHAs </plain></SENT>
<SENT sid="2" pm="."><plain>In addition, two groups of ten patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> were investigated either before and after introducing insulin treatment (add-on insulin group) or before and after add-on OHA therapy to <z:chebi fb="0" ids="6801">metformin</z:chebi> (add-on OHA group) </plain></SENT>
<SENT sid="3" pm="."><plain><z:mp ids='MP_0003674'>Oxidative stress</z:mp> was estimated from 24 h urinary excretion rates of <z:chebi fb="0" ids="34505">8-isoprostaglandin F2alpha</z:chebi> (8-iso-<z:chebi fb="0" ids="15553">PGF2alpha</z:chebi>) </plain></SENT>
<SENT sid="4" pm="."><plain>HbA(1c) was assessed and mean amplitude of glycaemic excursions (MAGE) was estimated by continuous monitoring </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The 24 h excretion rate of 8-iso-<z:chebi fb="0" ids="15553">PGF2alpha</z:chebi> (median [range] picomoles per millimole of <z:chebi fb="0" ids="16737">creatinine</z:chebi>) was much higher (p &lt; 0.0001) in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients treated with OHAs alone (112 [26-329]) than in the type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> group (65 [29-193]) and the type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> group treated with insulin (69 [30-198]) </plain></SENT>
<SENT sid="6" pm="."><plain>It was associated with HbA(1c) (F = 12.9, p = 0.0008) and MAGE (F = 7.7, p = 0.008) in non-insulin-treated, but not in insulin-treated patients </plain></SENT>
<SENT sid="7" pm="."><plain>A significant reduction in 24 h excretion rate of 8-iso-<z:chebi fb="0" ids="15553">PGF2alpha</z:chebi> from 126 (47-248) to 62 (35-111] pmol/mmol of <z:chebi fb="0" ids="16737">creatinine</z:chebi> was observed in the add-on insulin group (p = 0.005) but not in the add-on OHA group </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS/INTERPRETATION: In type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, insulin exerts an inhibitory effect on <z:mp ids='MP_0003674'>oxidative stress</z:mp>, a <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorder</z:e> that is significantly activated by sustained <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and <z:chebi fb="105" ids="17234">glucose</z:chebi> variability in non-insulin-treated type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>